Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosis

Documenti analoghi

• Correction to “Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis”
  Pubblicazione: (2024)
• Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease
  di: Yi‐Ting Chen, et al.
  Pubblicazione: (2024)
• Bifidobacterium Lactobacillus Triple Viable Alleviates Slow Transit Constipation by Regulating Gut Microbiota and Metabolism
  di: Mei Luo, et al.
  Pubblicazione: (2025)
• CTP 0301 for Bowel Preparation: Promising, yet Methodology Requires More Rigorous
  di: Shanshan Mei, et al.
  Pubblicazione: (2025)
• LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease
  di: Yong Wen Leow, et al.
  Pubblicazione: (2024)